It refers to a Marketing Autorization (MA) valid exclusively in the Republic of Cyprus. The procedure for issuing a National MA can be followed for pharmaceutical products that are not marketed in other member states (mainly applications for generics or well-established use medicinal products), as well as linear extensions of pharmaceutical products (e.g. different strength, route of administration, pharmaceutical form, etc.) that have been approved through a national procedure .
More information you can find in “The Medicines for Human Use (Quality, Supply and Price Control) Law of 2001 (L. 70(I)/2001) until 2020.”